Everything below concerns immunomodulator. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-04-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Thymosin alpha 1 was identified in 1977 as a component of thymosin fraction 5, a heterogeneous preparation used in early studies of thymic function. Investigators purified the active material and determined its amino acid sequence, which enabled chemical synthesis. Work in the following decades concentrated on T-cell maturation and immune reconstitution in animals and small human cohorts. Early preparations varied in composition, so results from that period are difficult to compare with studies using defined synthetic peptide.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
Laboratory work indicates that the peptide acts on cells of both the innate and adaptive immune systems. Reported effects include signalling through Toll-like receptors on dendritic cells, enhanced T-cell maturation, and increased natural killer cell activity. These actions are described largely from cell-culture and animal experiments, and the precise receptor-level events remain incompletely defined. Studies in humans have generally measured immune markers rather than a single defined molecular target. The resulting picture remains partly descriptive.
| Property | Value | Notes |
|---|---|---|
| First described | 1977 | Reported as a component of thymosin fraction 5 |
| Sequence length | 28 amino acids | N-terminal residue is acetylated |
| Net charge at neutral pH | Negative | Reflects a high proportion of acidic residues |
| Principal studied uses | Chronic hepatitis B and vaccine adjuvant | Research uses outnumber approved indications |
| Regulatory status | Approved in a limited number of countries | Not approved in the United States or most of Europe |
胸腺素α1（thymosin alpha 1，Tα1）是一种由28个氨基酸组成的酸性肽，N端被乙酰化，分子量约为3108道尔顿。该肽最早从牛胸腺组织提取物中分离，属于胸腺素组分5的一个成分。其序列在不同哺乳动物中高度保守，提示其具有基本的生物学功能。名称中的“α1”指其在电泳中的迁移位置，并非表示亚型编号。它既存在于胸腺，也存在于脾脏和淋巴结等免疫组织。
20世纪70年代，研究者从胸腺提取物中纯化出多种小肽，Tα1是其中被较早表征的一种。最初的制备依赖组织匀浆和层析步骤，产量低且成分复杂。随着固相肽合成技术成熟，实验室和工业界能够生产与天然序列一致的合成版本。合成肽的纯度可达95%以上，并可通过反相高效液相色谱和质谱进行鉴定。这一转变使研究不再依赖动物胸腺来源。
Thymosin alpha 1 is a short peptide of 28 amino acid residues that derives from the amino terminal region of a larger precursor protein known as prothymosin alpha. The peptide carries an acetyl group on its first residue and contains no disulfide bonds or carbohydrate chains. Its sequence is highly conserved across mammalian species, which is one reason laboratories treat it as a molecule with a defined and reproducible structure rather than a variable tissue extract. The name follows an early naming convention for thymus-derived fractions and does not imply that the peptide acts as a hormone in the classical endocrine sense.
Biologically, the peptide is studied mainly in the context of immune cell development and regulation. It is produced in the thymus and in several other tissues, and it appears to influence the maturation and activity of T cells and other immune populations. Laboratory work describes effects on cytokine production, on the balance between T cell subsets, and on the function of dendritic cells. Much of this evidence comes from cell culture and animal models, so the extent to which the same pathways operate in humans remains an open question.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Whether the free 28-residue peptide circulates in human tissue remains debated. The best-documented human source is prothymosin alpha, a larger acidic protein that carries the sequence at its N-terminus. Reports of measurable peptide levels in serum and lymphoid tissue exist, yet some of that signal may come from cross-reacting fragments or from the parent protein. Most reviews therefore treat prothymosin alpha as the established human molecule and describe independent circulation of the small peptide as an unresolved question.
Keyhole limpet hemocyanin (KLH) is a large, multisubunit, oxygen-carrying, metalloprotein that is found in the hemolymph of the giant keyhole limpet, Megathura crenulata, a species of keyhole limpet that lives off the coast of California, from Monterey Bay to Isla Asuncion off Baja California.
=== Addiction and dependence liability === DMT, like other serotonergic psychedelics, is considered to be non-addictive with low abuse potential. A study examining substance use disorder for the DSM-IV reported that almost no hallucinogens produced dependence, unlike psychoactive drugs of other classes such as stimulants and depressants. At present, there have been no studies that report drug withdrawal syndrome with termination of DMT, and dependence potential of DMT and the risk of sustained psychological disturbance may be minimal when used infrequently; however, the physiological dependence potential of DMT and ayahuasca has not yet been documented convincingly.
Alexander of the United States Army Intelligence and Security Command; Hal Puthoff, of SRI International in California; remote viewer Ingo Swann and the subsequent Stargate Project, at Fort Meade in Maryland; Keith Harary, who worked with Russell Targ. Narrated by Jim Schnabel, produced by Alex Graham, directed by Bill Eagles, made by Wall to Wall Television 3 September Cybersecrecy, the mathematician Fred Piper of the Information Security Group; the UK gave out Enigma machines to Commonwealth countries for secret telecommunications, without telling these countries that the UK could read every message; Phil Zimmermann, inventor of the PGP encryption algorithm; Simon Davies (privacy advocate); when at MIT in 1976, Whitfield Diffie found how to make encryption much more secure, to have public key encryption; Mark Rotenberg; Dorothy E. Denning, and criminal methods of encryption; Wayne Madsen (journalist); Ross J. Anderson of the Department of Computer Science and Technology, University of Cambridge and how the (French-designed) A5/1 encryption for the European mobile network in the 1990s had weak security; journalist Stephen Dorril; the NSA's Clipper chip; journalist James Bamford, author of The Puzzle Palace; a documentary in the style of Panorama. Produced by David Frank, directed by Martin Durkin, made by RDF Media 10 September Guru Busters investigates the activities of people in India who claim to have mystical powers. Producer and directed by Robert Eagle, narration by Art Malik, production company Eagle & Eagle.
Sources: en.wikipedia.org
=== Production and fermentation === First, raw milk (either from cattle, goats or sheep) is mixed and pasteurized at 72 °C (162 °F) for 15 seconds. Then, acidification occurs: a starter culture, such as Streptococcus lactis, is added in order to change lactose to lactic acid, thus changing the acidity of the milk and turning it from liquid to solid. The next step is coagulation, where rennet, a mixture of rennin and other materials found in the stomach lining of a calf is added to solidify the milk further. Following this, thick curds are cut typically with a knife to encourage the release of liquid or whey. The smaller the curds are cut, the thicker and harder the resulting cheese will become. After the curds have been ladled into containers in order to be drained and formed into a full wheel of cheese, the Penicillium roqueforti inoculum is sprinkled on top of the curds along with Brevibacterium linens. Then, the curd granules are knit in molds to form cheese loaves with a relatively open texture. Next, whey drainage continues for 10–48 hours in which no pressure is applied, but the molds are inverted frequently to promote this process. Salt is then added to provide flavor as well as to act as a preservative so the cheese does not spoil through the process of brine salting or dry salting for 24–48 hours. The final step is ripening the cheese by aging it. When the cheese is freshly made, there is little to no blue cheese flavor development. Usually, a fermentation period of 60–90 days is needed before the flavor of the cheese is typical and acceptable for marketing.
Diverse perspectives on well-being are found in religious and other traditional belief systems, where well-being often serves as a goal of spiritual practice. In various traditional forms of Hinduism, the highest kind of well-being is not determined by objective external conditions. Instead, it depends primarily on experiential knowledge of the self, brought about through practices like self-inquiry and meditation. Buddhism identifies suffering as a central aspect of all existence. It aims to produce well-being by eliminating the causes of suffering, such as desire and ignorance, achieved through the practice of Buddhist virtues, like compassion, loving-kindness, and equanimity. From the perspective of Confucianism, well-being consists in virtuous activity as a process leading to sagehood and is associated with harmonious relationships and social responsibility. According to Taoism, a life high in well-being is characterized by effortless action that is in harmony with the Tao—the natural way of the universe—and guided by spontaneous dispositions. The Christian tradition holds that the personal connection to God is a central factor of well-being, which may manifest in virtuous activity or contemplation of God. According to the teachings of Islam, well-being is achieved by dedicating one's life as much as possible to worshiping Allah and fulfilling His will, as expressed in the Quran. Well-being is also a topic in various biological sciences with a focus on physiological factors. Research from twin studies suggests that genetic composition is an impactful determinant.
==== Industrial peeling ==== Efficient techniques have been developed by the industry to peel large quantities of tubers while limiting losses and waste that must then be recycled, usually in animal feed. These techniques are abrasive peeling (the one that produces the most losses), soda peeling (chemical peeling by soaking in a bath of sodium hydroxide at high temperature, followed by rinsing), or steam peeling (a high-pressure steam bath removes the skin from the tubers, which is then vacuumed). The latter method minimizes vitamin losses.
Sources: en.wikipedia.org
Trials differ in patient population, dose schedule, background treatment, and the endpoints used to judge success. Many are small and single-center, so random variation can dominate the reported effects.
Authorization is limited to a small number of countries and covers specific indications such as chronic hepatitis B and vaccine adjuvant use. Availability and labelling differ by jurisdiction.
Most reviews describe it as an immunomodulatory agent with an uncertain clinical effect. They generally call for larger, better-controlled trials before firm conclusions are drawn.
It corresponds to the first 28 amino acids of thymosin beta-4, a larger protein found in many tissues. The fragment is acetylated at its N-terminus and is produced synthetically for research and pharmaceutical use. Synthetic and natural forms share the same sequence.